148 related articles for article (PubMed ID: 9381293)
1. [Minimal residual disease in chronic myeloid disease. A practical focus].
Casado LF; Steegmann JL
Sangre (Barc); 1997 Apr; 42 Suppl 1():13-6. PubMed ID: 9381293
[No Abstract] [Full Text] [Related]
2. ABL gene fuses BCR during t(20;22) results in Philadelphia-negative, but BCR/ABL-positive chronic myeloid leukemia.
Ito Y; Shimamoto T; Kuriyama Y; Nakajima A; Sumi M; Watanabe Y; Beppu H; Ohtsubo K; Ohyashiki K
Leukemia; 2002 May; 16(5):951-2. PubMed ID: 11986960
[No Abstract] [Full Text] [Related]
3. Monitoring of residual disease in chronic myelogenous leukemia: methodological approaches and clinical aspects.
Lion T
Leukemia; 1996 May; 10(5):896-900; discussion 901-6. PubMed ID: 8656687
[No Abstract] [Full Text] [Related]
4. Persistence of dormant leukemic progenitors during interferon-induced remission in chronic myelogenous leukemia. Analysis by polymerase chain reaction of individual colonies.
Talpaz M; Estrov Z; Kantarjian H; Ku S; Foteh A; Kurzrock R
J Clin Invest; 1994 Oct; 94(4):1383-9. PubMed ID: 7929813
[TBL] [Abstract][Full Text] [Related]
5. Frequent detection of minimal residual disease by use of the polymerase chain reaction in long-term survivors after bone marrow transplantation for chronic myeloid leukemia.
Pignon JM; Henni T; Amselem S; Vidaud M; Duquesnoy P; Vernant JP; Kuentz M; Cordonnier C; Rochant H; Goossens M
Leukemia; 1990 Feb; 4(2):83-6. PubMed ID: 2406520
[TBL] [Abstract][Full Text] [Related]
6. [Bcr-abl translocation: diagnostic methods and clinical value].
Pignon JM
Ann Biol Clin (Paris); 1998; 56(1):57-63. PubMed ID: 9754223
[TBL] [Abstract][Full Text] [Related]
7. Thiotepa, busulfan and cyclophosphamide as a preparative regimen for allogeneic transplantation for advanced chronic myelogenous leukemia.
Przepiorka D; Khouri I; Thall P; Mehra R; Lee MS; Ippoliti C; Giralt S; Gajewski J; van Besien K; Andersson B; Körbling M; Deisseroth AB; Champlin R
Bone Marrow Transplant; 1999 May; 23(10):977-81. PubMed ID: 10373061
[TBL] [Abstract][Full Text] [Related]
8. [Monitoring of Ph chromosome by fluorescence in situ hybridization in chronic myeloid leukemia].
Takahashi N; Miura I
Rinsho Ketsueki; 2000 Apr; 41(4):272-4. PubMed ID: 10846453
[No Abstract] [Full Text] [Related]
9. Comparison of bone marrow high mitotic index metaphase fluorescence in situ hybridization to peripheral blood and bone marrow real time quantitative polymerase chain reaction on the International Scale for detecting residual disease in chronic myeloid leukemia.
Lundán T; Juvonen V; Mueller MC; Mustjoki S; Lakkala T; Kairisto V; Hochhaus A; Knuutila S; Porkka K
Haematologica; 2008 Feb; 93(2):178-85. PubMed ID: 18223279
[TBL] [Abstract][Full Text] [Related]
10. Chronic myeloid leukemia: current application of cytogenetics and molecular testing for diagnosis and treatment.
Tefferi A; Dewald GW; Litzow ML; Cortes J; Mauro MJ; Talpaz M; Kantarjian HM
Mayo Clin Proc; 2005 Mar; 80(3):390-402. PubMed ID: 15757021
[TBL] [Abstract][Full Text] [Related]
11. The BCR gene and philadelphia chromosome-positive leukemogenesis.
Laurent E; Talpaz M; Kantarjian H; Kurzrock R
Cancer Res; 2001 Mar; 61(6):2343-55. PubMed ID: 11289094
[No Abstract] [Full Text] [Related]
12. Interpretation of submicroscopic deletions of the BCR or ABL gene should not depend on extra signal-FISH: problems in interpretation of submicroscopic deletion of the BCR or ABL gene with extra signal-FISH.
Kim YR; Cho HI; Yoon SS; Park S; Kim BK; Lee YK; Chun H; Kim HC; Lee DS
Genes Chromosomes Cancer; 2005 May; 43(1):37-44. PubMed ID: 15723338
[TBL] [Abstract][Full Text] [Related]
13. [Chronic myeloid leukemia: progress and prospects].
Baccarani M; Russo D; Fanin R
Haematologica; 1991 Jun; 76 Suppl 3():40-5. PubMed ID: 1752539
[No Abstract] [Full Text] [Related]
14. Typical chronic myelogenous leukemia with e19a2 BCR/ABL transcript. Report of two cases.
Martínez-López J; Ayala R; Albizua Q
Haematologica; 2002 Aug; 87(8):ELT35. PubMed ID: 12161380
[No Abstract] [Full Text] [Related]
15. Detection of the Philadelphia chromosome in paraffin-embedded tissue by fluorescence in situ hybridization.
Brynes RK; McCourty A; Ho JP; Traweek ST; Snyder DS; Slovak ML
Mod Pathol; 1994 Jun; 7(5):565-9. PubMed ID: 7937723
[TBL] [Abstract][Full Text] [Related]
16. [Leukemogenesis and new therapy development: the example of chronic myelogenous leukemia].
Etienne G; Mahon FX
Bull Cancer; 2001 Jul; 88(7):651-8. PubMed ID: 11495816
[TBL] [Abstract][Full Text] [Related]
17. [Use of cytogenetic and molecular biology in the detection of chronic myeloid leukemia].
Michalová K; Zemanová Z; Haskovec C; Rypácková B; Brdicka R
Cas Lek Cesk; 1992 Dec; 131(24-25):729-32. PubMed ID: 1288873
[TBL] [Abstract][Full Text] [Related]
18. [The monitoring of residual disease for chronic myelogenous leukemia patients treated with imatinib mesylate: detection of T315I mutation in ATP binding site of BCR/ABL gene].
Miyanishi S; Umeki K; Hayashi T; Fukutsuka K; Okumura A; Kishimori C
Rinsho Byori; 2003 Oct; 51(10):1023-9. PubMed ID: 14653203
[TBL] [Abstract][Full Text] [Related]
19. [Genetic diagnosis of chronic myeloid leukemia].
Kato C; Naoe T
Nihon Rinsho; 2001 Dec; 59(12):2336-41. PubMed ID: 11766335
[TBL] [Abstract][Full Text] [Related]
20. Detection and quantification of leukemia-specific rearrangements.
Hochhaus A
Methods Mol Med; 2002; 68():67-96. PubMed ID: 11901513
[No Abstract] [Full Text] [Related]
[Next] [New Search]
